top of page
  • Glenn Hearson

ACCORD: Study to Assess Multiple Candidate Agents for the Treatment COVID-19

Updated: Sep 5, 2022

We have recently commenced the #priorityCOVIDresearch ACCORD study, A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients.

The ACCORD study is prioritised by the NIHR as one of the urgent public health COVID-19 studies.

This research study is being done to test whether medicines which we think may work against SARS-CoV-2 might be able to help people with #COVID-19. At the moment, there are not any approved medicines to treat COVID-19.

Hospitals, researchers and the UK Government are working together to see if existing treatments for other conditions or diseases may be used to treat people with COVID-19.

To do this, several treatments will be tested, one at a time, in people with COVID-19. Medications tested in this study are investigational, which means they have not been approved by health authorities, such as the European Medicines Agency (EMA), for treating COVID-19.

All participants taking part in this study will continue to receive the currently accepted standard-of-care for COVID-19.

The Principle Investigator is, Professor Tim Harrison

This research study is now fully completed



bottom of page